Judge Invalidates Reissue Patent For Pfizer's Celebrex

Law360, Washington (March 12, 2014, 7:05 PM EDT) -- A Virginia federal judge on Wednesday invalidated a key Pfizer Inc. reissue patent covering methods for administering its blockbuster arthritis drug Celebrex, a ruling exposing the company to competition from generics makers.

U.S. District Judge Arenda L. Wright Allen said that U.S. Patent Number RE44048 was invalid under the judicial doctrine of obviousness-type double patenting, which prohibits a party from obtaining a new patent with claims that are not patentability distinct from claims in an earlier patent, according to an order granting partial summary judgment....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.